Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Conatus Pharmaceuticals Inc. (CNAT) was $0.30. Currently, the 1st Resistance Point for this stock is $0.33, with a 2nd Resistance Point sitting at $0.35. Meanwhile, this company’s stock has a 1st Support Level at $0.27 and a 2nd Support Level at $0.23. In the last full month, these shares have lost -$0.03, or -7.75%. In the past three months, this stock’s price has fallen by -$0.61, or -67.11%. This year-to-date, Conatus Pharmaceuticals Inc. (CNAT) shares have lost -$1.43, or -82.66%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Conatus Pharmaceuticals Inc. (CNAT) stock, 100% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Sell .”
With 33,170 K shares outstanding, this company currently has a market capitalization of $9,885K. Conatus Pharmaceuticals Inc. (CNAT) generates $33,590 K in annual sales, amounting to annual net income of -$18,010 K. This stock has generated a 1-Year Total Return of -92.29%, a 3-Year Total Return of -84.29%, and a 5-year Total Return of -95.28%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Jun-19, Conatus Pharmaceuticals Inc. (CNAT) reported earnings of -$0.02 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.12 per share, representing a 0.1 difference and -83.33% surprise. In the previous quarter ending in Mar-19, the reported earnings of -$0.14 represented a -0.02 difference from the consensus estimate calling for -$0.12 per share, which was a -16.67% surprise.
For the current fiscal quarter, which is set to end in 09/2019, the average earnings estimate is -$0.12 per share. This estimate came from a total of 1 Wall Street Analysts. Of those market experts, the high estimate was -$0.12 and the low estimate was -$0.12. In the year-ago quarter, Conatus Pharmaceuticals Inc. (CNAT) generated per-share earnings of -$0.15. If the analysts are correct about the current quarter’s earnings, the growth will be +20.00%.
Turning our focus now to insider trading activity, there have been 0 purchases (0 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 0 insider buys amounting to 0 shares and 0 insider sales amounting to 0 shares. In the past full year, 2 insider purchases were made (involving 3,585 shares) and 0 insider sell-offs equivalent to 0 shares.
Moving onto liquidity, Conatus Pharmaceuticals Inc. (CNAT) has a Current Ratio of 2.56, a Quick Ratio of 2.56 and a Cash Ratio of 2.20.